share_log

丽珠集团(000513.SZ):目前已布局了P-CAB产品,片剂产品的I期临床试验已完成

livzon pharmaceutical group inc. (000513.SZ): Currently has deployed P-CAB products, and the Phase I clinical trial of tablet products has been completed.

Gelonghui Finance ·  Oct 31, 2024 03:58

Gelonghui October 31st丨Livzon Pharmaceutical Group Inc. (000513.SZ) stated when accepting a specific object investigation on October 31, 2024, that the company is continuously enriching the product portfolio of gastrointestinal products. Currently, P-CAB products have been laid out, and the phase I clinical trial of tablet products has been completed. An application has been submitted to the CDE for direct entry into phase III clinical trials without phase II. The injection form is also in simultaneous development.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment